TBPH Stock Recent News

DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, randomized, registrational revefenacin Phase 3 trials (Trials 0126 [NCT02459080] and 0127 [NCT02512510]) for YUPELRI, the first and only FDA approved once-daily nebulized long-acting muscarinic antagonist (LAMA), evaluating the area under the curve (AUC) lung function effects in moderate-to-very-severe chronic obstructive pulmonary disease (COPD) patients.  These data and analyses, published in the International Journal of Chronic Obstructive Pulmonary Disease, reinforce that YUPELRI provides consistent and durable improvements in lung function, as compared with placebo, over a full 24-hours.

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference.

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainright David Risinger - Leerink Partners Ernie Rodriguez - TD Cowen Liisa Bayko - Evercore ISI Operator Ladies and gentlemen, good afternoon.

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.13 per share a year ago.

Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approved Now expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months later Q2 2024 TRELEGY net sales of $1.065 billion, increasing the likelihood of achieving up to $50 million of milestones in 2024 Q2 2024 ending cash balance of $96.1 million DUBLIN , Aug. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the second quarter of 2024. "YUPELRI net sales decreased 1% from the prior quarter, owing to near-term headwinds from an evolved channel mix and a lower realized net price," said Rick Winningham, Theravance Biopharma CEO.

DUBLIN , July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference.

DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, August 5, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.